Search
EGT-201
go.drugbank.com/drugs/DB17648ExperimentalEGT-201 is an adeno-associated viral vector serotype 9 (AAV9) vector-based gene therapy consisting of the alpha-N-acetyglucosaminidase (NAGLU) transgene. … Developed by Esteve Pharmaceuticals, it is being investigated for Sanfilippo syndrome type B.[L45939]
EGT-301
go.drugbank.com/drugs/DB17649ExperimentalEGT-301 is a gene therapy being investigated for Hunter Syndrome. … It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome
AVR-RD-02
go.drugbank.com/drugs/DB17650InvestigationalAVR-RD-02 is being investigated in Gaucher Disease.[L45958] … It consists of autologous CD34+ enriched hematopoietic stem cells (HSCs) that have been genetically modified _ex vivo_ with a lentiviral vector (LV) to contain a ribonucleic acid (RNA) transcript that,
Reloxiliase
go.drugbank.com/drugs/DB17653ExperimentalReloxiliase is a first-in-class, oral crystalline formulation of the oxalate-specific, microbial enzyme oxalate decarboxylase. It is being investigated for the treatment of hyperoxaluria.[A258823]
ABX1100
go.drugbank.com/drugs/DB17655InvestigationalABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle. … It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.[L45978]
RP-L301
go.drugbank.com/drugs/DB17661InvestigationalRP-L301 is a lentiviral vector containing the human liver and erythroid pyruvate kinase gene.
rAAV9-rsATP7A
go.drugbank.com/drugs/DB17664ExperimentalA recombinant adeno-associated viral vector gene therapy under investigation for the treatment of Menkes disease.
SYNB1353
go.drugbank.com/drugs/DB17666InvestigationalSYNB1353 is a strain of the probiotic bacteria _Escherichia coli_ (_E. coli_) type Nissle and an engineered probiotic drug. … [A258833] Developed by Synlogic Operating Company, Inc., SYNB1353 is being investigated for the treatment of homocystinuria.
SYNB1020
go.drugbank.com/drugs/DB17667Investigationaldiscontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. … SYNB1020 is an engineered strain of _Escherichia coli_ Nissle 1917 developed by Synlogic Inc.
PRX-OTC
go.drugbank.com/drugs/DB17680ExperimentalPRX-OTC is an intracellular enzyme replacement therapy designed to replace missing or defective enzyme in patients with ornithine transcarbamylase deficiency.